Glaukos Corp is a US-based ophthalmic medical technology and pharmaceutical company focused on treatments for glaucoma, corneal disorders, and retinal diseases. Its commercial portfolio includes the iStent family of micro-scale surgical devices, such as iStent, iStent inject W, and iStent infinite, which are implanted during cataract or standalone glaucoma surgery to improve aqueous outflow. The company also markets iDose TR, an intracameral procedural pharmaceutical implant that delivers long-duration glaucoma therapy inside the eye, and Photrexa, a bio-activated pharmaceutical therapy for keratoconus. Glaukos sells primarily to ophthalmic surgeons, hospitals, and ambulatory surgery centers, mainly in the United States, with additional operations in select international markets. Revenue comes from sales of surgical devices and pharmaceutical products, complemented by research and development activities and a pipeline of investigational therapies for corneal and retinal conditions.